Vanguard Group Inc. Increases Stock Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Vanguard Group Inc. increased its position in Bausch Health Companies Inc. (NYSE:BHC) by 1.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,684,859 shares of the company’s stock after acquiring an additional 145,078 shares during the quarter. Vanguard Group Inc. owned about 3.23% of Bausch Health Companies worth $94,460,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of BHC. American Century Companies Inc. boosted its position in shares of Bausch Health Companies by 10.6% during the 4th quarter. American Century Companies Inc. now owns 27,236 shares of the company’s stock valued at $220,000 after acquiring an additional 2,600 shares during the last quarter. Northwest & Ethical Investments L.P. increased its holdings in shares of Bausch Health Companies by 119.7% in the 4th quarter. Northwest & Ethical Investments L.P. now owns 71,139 shares of the company’s stock worth $574,000 after buying an additional 38,755 shares during the last quarter. Magnetar Financial LLC purchased a new stake in shares of Bausch Health Companies during the 4th quarter valued at $151,000. Intact Investment Management Inc. grew its position in Bausch Health Companies by 38.3% in the fourth quarter. Intact Investment Management Inc. now owns 261,300 shares of the company’s stock worth $2,112,000 after acquiring an additional 72,300 shares in the last quarter. Finally, Kendall Capital Management increased its stake in Bausch Health Companies by 43.4% in the fourth quarter. Kendall Capital Management now owns 17,995 shares of the company’s stock valued at $145,000 after acquiring an additional 5,445 shares during the last quarter. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Performance

BHC opened at $5.03 on Thursday. The stock’s 50 day moving average price is $6.65 and its 200-day moving average price is $7.59. Bausch Health Companies Inc. has a 52-week low of $3.96 and a 52-week high of $9.87. The stock has a market capitalization of $1.85 billion, a PE ratio of -41.87, a price-to-earnings-growth ratio of 0.37 and a beta of 0.43.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.44). The company had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. Research analysts forecast that Bausch Health Companies Inc. will post 4.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on BHC shares. Jefferies Financial Group reiterated a “hold” rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Royal Bank of Canada lowered their price target on shares of Bausch Health Companies from $9.00 to $8.50 and set a “sector perform” rating for the company in a research note on Monday. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Bausch Health Companies presently has an average rating of “Hold” and an average price target of $7.17.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.